Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

被引：0
|
作者：
Martini, Dylan J.
Shabto, Julie M.
Liu, Yuan
Carthon, Bradley Curtis
Speak, Alexandra
Hitron, Elise
Russler, Greta
Caulfield, Sarah
Ogan, Kenneth
Harris, Wayne
Master, Viraj A.
Kucuk, Omer
Bilen, Mehmet Asim
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Emory Univ, Dept Biostat, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Bioinformat, Atlanta, GA 30322 USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Emory Univ, Sch Med, Dept Pharmaceut Serv, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
    De Velasco, G.
    Alonso-Gordoa, T.
    Rodriguez-Moreno, J. F.
    Duran, I.
    Carretero-Gonzalez, A.
    Martin-Soberon, M.
    Gutierrez Banos, J. L.
    Guerrero-Ramos, F.
    Duenas, M.
    Castellano Gauna, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S698 - S699
  • [22] Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo)
    Zahoor, Haris
    Barata, Pedro C.
    Jia, Xuefei
    Hobbs, Brian P.
    Martin, Allison
    Allman, Kimberly D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Lin, X.
    Kalanovic, D.
    McKay, R.
    Perkins, J.
    Simantov, R.
    Choueiri, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S642 - S642
  • [24] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Efficacy and safety of sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC) and lung metastases (mets) only at baseline
    Shinohara, Nobuo
    Akaza, Hideyuki
    Tomita, Yoshihiko
    Yuasa, Takeshi
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Ozono, Seiichiro
    Mugiya, Soichi
    Miki, Tsuneharu
    Uemura, Hirotsugu
    Nonomura, Norio
    Takahashi, Masayuki
    Hasegawa, Yoshihiro
    Ueda, Eiji
    Shibata, Atsushi
    Kawai, Norisuke
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC)
    Kinsey, Emily
    Brown, Landon
    Kao, Chester
    Healy, Patrick
    Harrison, Michael
    McNamara, Megan
    Armstrong, Andrew
    Ramalingham, Sundhar
    George, Daniel
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [27] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features
    Barroso-Sousa, Romualdo
    Munhoz, Rodrigo Ramella
    Fonseca, Leonardo Gomes
    de Sousa Fede, Angelo Bezerra
    Marques Linck, Rudinei Diogo
    Venchiarutti Moniz, Camila Motta
    Mak, Milena Perez
    Souza, Ciro Eduardo
    Hoff, Paulo M.
    Dzik, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).
    Ivanyi, Philipp
    Eggers, Hendik
    Seidel, Christoph Alexander
    Reuter, Christoph
    Ganser, Arnold
    Gruenwald, Viktor
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon C.
    Desai, Kunal
    Wei, Wei
    Kinsey, Emily N.
    Kao, Chester
    George, Daniel J.
    Rini, Brian, I
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
12345